The Interplay Between Epigenetics and Inflammation in Chronic Diseases

A special issue of Epigenomes (ISSN 2075-4655).

Deadline for manuscript submissions: 31 January 2025 | Viewed by 395

Special Issue Editor


E-Mail
Guest Editor
Nephrology, School of Medicine, University of Connecticut Health Center, Farmington, CT 06030-1405, USA
Interests: immunology; inflammation; fibrosis; molecular mechanisms; epigenetic regulation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We aim to explore the dynamic interplay between epigenetic mechanisms and chronic inflammatory processes. Chronic inflammation underlies a myriad of diseases, altering the epigenetic landscape across various conditions. We are seeking submissions of original research articles, reviews, and perspective pieces that delve into how epigenetic modifications such as DNA methylation, histone modification, and non-coding RNA expression contribute to the initiation, progression, and persistence of chronic inflammation. Contributions might also focus on the potential of epigenetic therapies to modulate inflammatory responses, offering new avenues for therapeutic intervention. By bringing together insights from diverse disciplines, this Special Issue seeks to deepen our understanding of the epigenetic foundations of inflammation and stimulate discussions on innovative strategies to manage inflammation across diseases. We invite researchers from molecular biology, immunology, pharmacology, and related fields to share their findings and viewpoints in this critical discourse.

Dr. Baihai Jiao
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetic modifications
  • inflammation
  • immune regulation
  • disease mechanisms

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop